ACADIA Pharmaceuticals Inc.(Exact name of small business issuer as specified in its charter)
Delaware
(State or other jurisdiction of incorporation or organization)
061376651
(IRS Employer Identification No.)
11085 Torreyana Road #100, San Diego, California 92121
(Address of principal executive offices)
858-558-2871
(Registrant's Telephone number)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On September 2, 2014, we issued a press release announcing that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to our proprietary compound, NUPLAZID[TM] (pimavanserin), for the treatment of psychosis associated with Parkinson's disease. A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ACADIA Pharmaceuticals Inc.
|
Date: September 2, 2014
| By: |
/s/ Glenn F. Baity |
|
| Name: Glenn F. Baity |
| Title: Vice President & General Counsel |
Exhibit Index
|
Exhibit No.
|
|
Description
|
|
EX-99.1
|
|
Press release dated September 2, 2014
|